Health

The Successor Of An HIV Drug Reduces Carbon Emissions By 26%

Medical Update Online

A groundbreaking report has uncovered that modifying the ingredients list or manufacturing methods of widely used medications can significantly reduce carbon emissions. This report, titled “Milligrams to Megatons” by Unitaid, highlights a reduction of 26 million tons of CO2 emissions—a figure that equals the entire carbon footprint of Geneva for ten years. Remarkably, these emissions have already been saved, as the changes are almost fully implemented.

The lifesaving HIV treatment dolutegravir (DTG), which is now utilized by 24 million people worldwide, serves as a prime example. Over 110 low and middle-income countries have adopted DTG as the preferred treatment option for HIV. The rapid voluntary licensing of DTG, including its pediatric version, to over a dozen generic manufacturers has driven down prices substantially. As a result, it is estimated that 1.1 million lives will be saved from HIV/AIDS-related deaths by 2027.

DTG’s predecessor, efavirenz, contained 1200 milligrams of active ingredient spread across three active compounds. In contrast, DTG contains only 650 milligrams of a single compound. Although this difference may seem minor—comparable to the weight of a few paper clips—it significantly impacts the medication’s carbon footprint, reducing it by a factor of 2.6.

Unitaid’s report is the first published research to compare the carbon footprints of commonly used medications. “This magnitude of carbon footprint reduction surpasses many hard-won achievements of climate mitigation in health and other sectors,” the report’s authors state. Since DTG began production and treatment in 2017, 2.6 million fewer tons of CO2 have been released into the atmosphere annually compared to if efavirenz had remained the standard treatment.

Health Policy Watch reports that the global medical sector’s carbon emissions account for approximately 5% of global emissions, surpassing the emissions of many large countries and amounting to 2.5 times the emissions of the aviation industry. This context underscores the significant impact that changes in pharmaceutical manufacturing can have on the environment.

“This report demonstrates that we can achieve significant health improvements while also making strides in reducing carbon emissions. By adopting innovative practices and prioritizing sustainability, we can ensure that medicines like DTG are not only effective but also environmentally responsible,” Vincent Bretin, Director of Unitaid’s Results and Climate Team, told Health Policy Watch.

Unitaid, a global public-private partnership, invests in new health products and solutions for low and middle-income countries. Their work has shown that it is possible to make substantial progress in both health outcomes and environmental sustainability. The shift to DTG from efavirenz is a testament to the potential of rethinking pharmaceutical formulations and manufacturing processes to achieve significant environmental benefits.

The findings of the “Milligrams to Megatons” report present a compelling case for the broader pharmaceutical industry to consider the environmental impacts of their products. The success of DTG suggests that similar strategies could be employed for other medications, potentially leading to further reductions in the sector’s carbon footprint.

The report also emphasizes the importance of collaboration among various stakeholders, including governments, pharmaceutical companies, and international organizations, to drive such changes. The rapid adoption and licensing of DTG exemplify how coordinated efforts can lead to both improved health outcomes and environmental sustainability.

The “Milligrams to Megatons” report by Unitaid highlights a significant opportunity for the pharmaceutical industry to contribute to global carbon reduction efforts. By reevaluating the ingredients and manufacturing processes of medications, it is possible to achieve substantial environmental benefits without compromising on health outcomes. The success of DTG serves as an inspiring model for future initiatives aimed at making the healthcare sector more sustainable.